Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

30.15 +0.66 (+2.24%)
Streaming Delayed Price Updated: 9:59 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oculis Holding AG - Ordinary shares

< Previous 1 2 3 Next >
News headline image
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
From Oculis Holding AG
Via GlobeNewswire
Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts ↗
Via Chartmill
Topics Earnings
News headline image
Oculis Reports Q1 2026 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
From Oculis Holding AG
Via GlobeNewswire
Oculis Holding AG (NASDAQ:OCS) Reports Q4 2025 Earnings Beat, Focus Remains on 2026 Clinical Catalysts ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Appoints Katie Kazem as Chief Legal Officer
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Oculis Holding AG (NASDAQ:OCS) Reports Q3 2025 Earnings Beat and Provides Key Clinical Pipeline Updates ↗
Oculis (OCS) beat Q3 2025 earnings estimates, extended cash runway into 2029, and advanced its late-stage ophthalmology pipeline with key clinical milestones ahead. 
Via Chartmill
Topics Earnings
News headline image
Oculis Reports Q3 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming November Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial 
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming September Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.